Corrigendum to "Adjuvant and first line chemotherapy use for endometrial cancer" [Gynecol. Oncol. Rep. 41 (2022) 101002]

Gynecol Oncol Rep. 2022 Dec 5:46:101112. doi: 10.1016/j.gore.2022.101112. eCollection 2023 Apr.

Authors

Anne Knisely^{1

2}, Yongmei Huang¹, Yeran Li³, Vimalanand S Prabhu³, Jason D Wright^{1

2

4}

Affiliations

¹ Columbia University College of Physicians and Surgeons, USA.
² Herbert Irving Comprehensive Cancer Center, USA.
³ Merck & Co., Inc., Kenilworth, NJ, USA.
⁴ New York Presbyterian Hospital, USA.

Abstract

[This corrects the article DOI: 10.1016/j.gore.2022.101002.].

© 2022.

Publication types

Published Erratum